Amit Saxena1, Marcin Bujak2, Olga Frunza1, Marcin Dobaczewski3, Carlos Gonzalez-Quesada3, Bao Lu4, Craig Gerard4, Nikolaos G Frangogiannis5. 1. The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, 1300 Morris Park Avenue Forchheimer G46B, Bronx, NY 10461, USA. 2. Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 3. The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, 1300 Morris Park Avenue Forchheimer G46B, Bronx, NY 10461, USA Department of Medicine, Baylor College of Medicine, Houston, TX, USA. 4. Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 5. The Wilf Family Cardiovascular Research Institute, Department of Medicine (Cardiology), Albert Einstein College of Medicine, 1300 Morris Park Avenue Forchheimer G46B, Bronx, NY 10461, USA Department of Medicine, Baylor College of Medicine, Houston, TX, USA nikolaos.frangogiannis@einstein.yu.edu.
Abstract
AIMS: The CXC chemokine CXCL10 is up-regulated in the infarcted myocardium and limits cardiac fibrosis by inhibiting growth factor-mediated fibroblast migration. CXCL10 signals by binding to its receptor CXCR3; however, recently CXCR3-independent CXCL10 actions have been suggested. Our study explores the role of CXCR3 signalling in myocardial infarction and investigates its involvement in mediating the anti-fibrotic effects of CXCL10. METHODS AND RESULTS: Wild-type and CXCR3 null mice underwent reperfused infarction protocols. CXCL10 was markedly induced in the infarct; in contrast, expression of the other two CXCR3 ligands, CXCL9 and CXCL11 was extremely low. CXCR3 loss did not affect scar size, geometric ventricular remodelling, collagen deposition, and systolic dysfunction of the infarcted heart. CXCR3 null mice had increased peak neutrophil recruitment and delayed myofibroblast infiltration in the infarcted heart, but exhibited comparable myocardial expression of pro-inflammatory cytokines and chemokines. In vitro, CXCL10 did not modulate Transforming Growth Factor (TGF)-β signalling, but inhibited basic fibroblast growth factor (bFGF)-induced cardiac fibroblast migration in both wild-type and CXCR3 null cells. Treatment of fibroblasts with heparinase and chondroitinase to cleave glycosaminoglycan chains abrogated the inhibitory effects of CXCL10 on cell migration. CONCLUSION: CXCR3 signalling does not critically regulate cardiac remodelling and dysfunction following myocardial infarction. The anti-fibrotic effects of CXCL10 in the healing infarct and in isolated cardiac fibroblasts are CXCR3-independent and may be mediated through proteoglycan signalling. Thus, administration of CXCR3-defective forms of CXCL10 may be an effective anti-fibrotic strategy in the remodelling myocardium without activating a potentially injurious, CXCR3-driven T cell response. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The CXC chemokine CXCL10 is up-regulated in the infarcted myocardium and limits cardiac fibrosis by inhibiting growth factor-mediated fibroblast migration. CXCL10 signals by binding to its receptor CXCR3; however, recently CXCR3-independent CXCL10 actions have been suggested. Our study explores the role of CXCR3 signalling in myocardial infarction and investigates its involvement in mediating the anti-fibrotic effects of CXCL10. METHODS AND RESULTS: Wild-type and CXCR3 null mice underwent reperfused infarction protocols. CXCL10 was markedly induced in the infarct; in contrast, expression of the other two CXCR3 ligands, CXCL9 and CXCL11 was extremely low. CXCR3 loss did not affect scar size, geometric ventricular remodelling, collagen deposition, and systolic dysfunction of the infarcted heart. CXCR3 null mice had increased peak neutrophil recruitment and delayed myofibroblast infiltration in the infarcted heart, but exhibited comparable myocardial expression of pro-inflammatory cytokines and chemokines. In vitro, CXCL10 did not modulate Transforming Growth Factor (TGF)-β signalling, but inhibited basic fibroblast growth factor (bFGF)-induced cardiac fibroblast migration in both wild-type and CXCR3 null cells. Treatment of fibroblasts with heparinase and chondroitinase to cleave glycosaminoglycan chains abrogated the inhibitory effects of CXCL10 on cell migration. CONCLUSION:CXCR3 signalling does not critically regulate cardiac remodelling and dysfunction following myocardial infarction. The anti-fibrotic effects of CXCL10 in the healing infarct and in isolated cardiac fibroblasts are CXCR3-independent and may be mediated through proteoglycan signalling. Thus, administration of CXCR3-defective forms of CXCL10 may be an effective anti-fibrotic strategy in the remodelling myocardium without activating a potentially injurious, CXCR3-driven T cell response. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Oliver Dewald; Pawel Zymek; Kim Winkelmann; Anna Koerting; Guofeng Ren; Tareq Abou-Khamis; Lloyd H Michael; Barrett J Rollins; Mark L Entman; Nikolaos G Frangogiannis Journal: Circ Res Date: 2005-03-17 Impact factor: 17.367
Authors: Marcin Bujak; Marcin Dobaczewski; Khaled Chatila; Leonardo H Mendoza; Na Li; Anilkumar Reddy; Nikolaos G Frangogiannis Journal: Am J Pathol Date: 2008-06-05 Impact factor: 4.307
Authors: Hermann E Wasmuth; Frank Lammert; Mirko Moreno Zaldivar; Ralf Weiskirchen; Claus Hellerbrand; David Scholten; Marie-Luise Berres; Henning Zimmermann; Konrad L Streetz; Frank Tacke; Sonja Hillebrandt; Petra Schmitz; Hildegard Keppeler; Thomas Berg; Edgar Dahl; Nikolaus Gassler; Scott L Friedman; Christian Trautwein Journal: Gastroenterology Date: 2009-04-01 Impact factor: 22.682
Authors: Ulf Panzer; Oliver M Steinmetz; Hans-Joachim Paust; Catherine Meyer-Schwesinger; Anett Peters; Jan-Eric Turner; Gunther Zahner; Felix Heymann; Christian Kurts; Helmut Hopfer; Udo Helmchen; Friedrich Haag; André Schneider; Rolf A K Stahl Journal: J Am Soc Nephrol Date: 2007-05-30 Impact factor: 10.121
Authors: Marcin Bujak; Marcin Dobaczewski; Carlos Gonzalez-Quesada; Ying Xia; Thorsten Leucker; Pawel Zymek; Vikas Veeranna; Andrew M Tager; Andrew D Luster; Nikolaos G Frangogiannis Journal: Circ Res Date: 2009-09-24 Impact factor: 17.367
Authors: Cecelia C Yates; Diana Whaley; Priya Kulasekeran; Wayne W Hancock; Bao Lu; Richard Bodnar; Joseph Newsome; Patricia A Hebda; Alan Wells Journal: Am J Pathol Date: 2007-06-28 Impact factor: 4.307
Authors: W W Hancock; B Lu; W Gao; V Csizmadia; K Faia; J A King; S T Smiley; M Ling; N P Gerard; C Gerard Journal: J Exp Med Date: 2000-11-20 Impact factor: 14.307
Authors: Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet Journal: J Exp Med Date: 2007-11-19 Impact factor: 14.307
Authors: Njabulo Ngwenyama; Ane M Salvador; Francisco Velázquez; Tania Nevers; Alexander Levy; Mark Aronovitz; Andrew D Luster; Gordon S Huggins; Pilar Alcaide Journal: JCI Insight Date: 2019-04-04
Authors: Olga Frunza; Ilaria Russo; Amit Saxena; Arti V Shinde; Claudio Humeres; Waqas Hanif; Vikrant Rai; Ya Su; Nikolaos G Frangogiannis Journal: Am J Pathol Date: 2016-03-03 Impact factor: 4.307